InfuSystem Holdings, Inc. (INFU)
NYSE · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1337013 · fiscal year ends in Dec
Closing price $14.01 on 30 Oct 2026; 52-week range $7.42 to $14.41.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $143.3M
- Revenue growth
- 2.5%
- Net income, last twelve months
- $8.5M
- Earnings per share
- $0.41
- Gross margin
- 57.5%
- Operating margin
- 9.3%
- Net margin
- 6.0%
- Free cash flow
- $22.9M
- Return on equity
- 14.4%
- Market value
- $279.0M
- Price to earnings
- 34.2x
- Cash
- $964.0K
- Debt
- $20.4M
- Debt to equity
- 0.35
- Shares outstanding
- 19.9M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $143.4M | $11.9M | $6.6M | $0.31 | $23.8M | 10-K filed 27 Feb 2026 |
| FY2024 | 31 Dec 2024 | $134.9M | $6.9M | $2.3M | $0.11 | $19.4M | 10-K filed 11 Mar 2025 |
| FY2023 | 31 Dec 2023 | $125.8M | $4.1M | $872.0K | $0.04 | $10.2M | 10-K filed 10 Apr 2024 |
| FY2022 | 31 Dec 2022 | $109.9M | $1.7M | $18.0K | $0.00 | $16.5M | 10-K filed 16 Mar 2023 |
| FY2021 | 31 Dec 2021 | $102.4M | $2.8M | $1.4M | $0.06 | $17.3M | 10-K filed 15 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $36.9M | $3.2M | $0.15 |
| Q1 FY2026 | 31 Mar 2026 | $33.7M | $1.0M | $0.05 |
| Q4 FY2025 | 31 Dec 2025 | $36.2M | $2.0M | $0.10 |
| Q3 FY2025 | 30 Sep 2025 | $36.5M | $2.3M | $0.11 |
| Q2 FY2025 | 30 Jun 2025 | $36.0M | $2.6M | $0.12 |
| Q1 FY2025 | 31 Mar 2025 | $34.7M | -$267.0K | -$0.01 |
| Q4 FY2024 | 31 Dec 2024 | $33.8M | $933.0K | $0.04 |
| Q3 FY2024 | 30 Sep 2024 | $35.3M | $1.8M | $0.08 |
Company events
The newest 8-K filings of 357 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Investor update | 7.01 |
| 17 Sep 2026 | 8-K | Investor update | 7.01 |
| 4 Aug 2026 | 8-K | Investor update | 7.01 |
| 4 Aug 2026 | 8-K | Results | 2.02 |
| 28 Jul 2026 | 8-K | Investor update | 7.01 |
| 18 May 2026 | 8-K | Investor update | 7.01 |
| 14 May 2026 | 8-K | Leadership change | 5.02 |
| 12 May 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07 |
| 7 May 2026 | 8-K | Results | 2.02 |
| 30 Apr 2026 | 8-K | Investor update | 7.01 |
| 19 Mar 2026 | 8-K | Auditor change | 4.01 |
| 16 Mar 2026 | 8-K | Investor update | 7.01 |
Every filing
The newest filings with the SEC of 593 held.
| Filed | Form | Period |
|---|---|---|
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 17 Sep 2026 | 8-K | 17 Sep 2026 |
| 4 Aug 2026 | 10-Q | 30 Jun 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 28 Jul 2026 | 8-K | 28 Jul 2026 |
| 18 May 2026 | 8-K | 12 May 2026 |
| 18 May 2026 | S-8 | – |
| 14 May 2026 | 8-K | 11 May 2026 |
| 12 May 2026 | 8-K | 11 May 2026 |
| 8 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 11 May 2026 | Lachance Carrie, President and CEO | Purchase | 1,000 | $8.46 | $8.5K | 238,123 | 12 May 2026 |
| 8 May 2026 | Gendron Paul Andrew, Director | Purchase | 5,000 | $8.88 | $44.4K | 70,000 | 12 May 2026 |
| 8 May 2026 | Lachance Carrie, President and CEO | Purchase | 2,000 | $8.83 | $17.7K | 237,123 | 12 May 2026 |
| 8 May 2026 | Steele Barry G, Executive VP and CFO | Purchase | 7,000 | $8.71 | $60.9K | 96,590 | 12 May 2026 |
| 2 Mar 2026 | Steele Barry G, Executive VP and CFO | Purchase | 2,064 | $9.16 | $18.9K | 88,000 | 2 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 28 Jul 2026 | BlackRock, Inc. | 13G | 6.4% | 1.3M |
| 17 Feb 2026 | Minerva Advisors LLC | 13G amended | 5.3% | 1.1M |
| 3 Dec 2025 | Minerva Advisors LLC | 13G | 5% | 1.0M |
| 13 Nov 2025 | AWM Investment Company, Inc. | 13G amended | 2.8% | 561.7K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 813.4K | -5.86% | 7.63 |
| 30 Sep 2026 | 864.1K | +6.37% | 5.22 |
| 15 Sep 2026 | 812.4K | +7.62% | 7.09 |
| 31 Aug 2026 | 754.9K | +2.87% | 8.44 |
| 14 Aug 2026 | 733.8K | -6.02% | 3.19 |
| 31 Jul 2026 | 780.8K | -4.15% | 5.72 |
| 15 Jul 2026 | 814.6K | -8.84% | 6.17 |
| 30 Jun 2026 | 893.6K | +558.88% | 2.04 |
Funds that hold it
From each fund's latest Form 13F.
122 funds held it at 30 Jun 2026: 51 added and 25 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 1,585,415 | $15.3M | +968,829 |
| Minerva Advisors LLC | 1,348,617 | $13.0M | +144,512 |
| First Eagle Investment Management, LLC | 1,240,000 | $12.0M | – |
| Punch & Associates Investment Management, Inc. | 834,750 | $8.1M | -3,175 |
| Vanguard Capital Management LLC | 790,775 | $7.6M | -69,488 |
| Acadian Asset Management LLC | 743,155 | $7.2M | +109,111 |
| Heartland Advisors Inc. | 700,000 | $6.8M | +190,000 |
| American Century Companies Inc. | 675,028 | $6.5M | +202,007 |
| Dimensional Fund Advisors LP | 599,289 | $5.8M | +5,001 |
| Renaissance Technologies LLC | 543,009 | $5.2M | -23,800 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B